GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

RVL Pharmaceuticals RVLPQ · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 26 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

RVL Pharmaceuticals — daily RVLPQ Delayed
Market value
$111
Last close × shares
Volume
3.2k
Shares, 26 Oct 2026

About RVL Pharmaceuticals

Its shares trade under the ticker RVLPQ. It has been listed since 12 October 2018. In the fiscal year to 31 December 2022, it reported revenue of $49.7m and a net loss of $51.7m. At that date it held total assets of $128.5m and shareholders' equity of $51.1m.

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey. The company went IPO on 2018-10-12. The firm is focused on the developing and commercialization of specialty products that target markets with underserved patient populations. The firm sells portfolio products consisting of promoted products and non-promoted products, which incorporate its Osmodex drug delivery system. The Company’s Osmodex drug delivery system uses osmotic pressure to provide a controlled drug release and is adaptable to many different combinations of immediate-release, extended-release and controlled- or delayed-release formulations that contain one or more drugs. The Company’s non-promoted product portfolio includes methylphenidate ER and venlafaxine extended-release tablets (VERT) as well as ANDAs and prescription dietary supplements. Its promoted products are led by Divigel and M-72 (methylphenidate hydrochloride extended-release tablets, 72 mg).

Figures and description from our data supplier, not checked against the company's own report.

More about RVL Pharmaceuticals →

Latest on RVL Pharmaceuticals

Our reporting

We have not reported on RVL Pharmaceuticals yet.

Next results

13 Nov 2026

Due on 13 Nov 2026. Analysts expect earnings of -0.23 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is RVL Pharmaceuticals's ticker?

RVL Pharmaceuticals trades as RVLPQ on its US listing, under ISIN IE00BF2HDL56.

What was RVL Pharmaceuticals's last closing price?

0.00 on 26 Oct 2026. The figure is in USD and is never converted.

When does RVL Pharmaceuticals next report results?

Results are expected on 13 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.